FIGURE 2.

High pyruvate dehydrogenase kinase 4 (PDK4) is associated with rituximab (RTX) resistance and low MS4A1/CD20 in diffuse large B‐cell lymphoma (DLBCL) cells. A, B, Real‐time quantitative PCR analysis of PDK4 and MS4A1 mRNA expression in DLBCL cell lines U2932, OCI‐ly7, and OCI‐ly8. C, Western blot analysis of PDK4 and CD20 protein levels in DLBCL cell lines U2932, OCI‐ly7, and OCI‐ly8. D, E, Annexin V‐phycoerythrin (PE)/7‐AAD double staining analysis of the three DLBCL cell lines treated with RTX (50 μg/mL). F, G, Mitochondrial membrane potential of DLBCL cells following treatment with RTX for 48 hours and stained with JC‐1 probe. Representative pictures of JC‐1 staining are shown. Scale bar, 25 μm. ***P < .001